By Fineline Cube 
Hua Medicine (HKG: 2552) announced a research collaboration agreement with GemVCare (GVC), a Hong Kong-based biotechnology company, to conduct a real-world clinical study focused on precision diabetes management using dorzagliatin, a first-in-class glucokinase activator (GKA) anti-diabetic drug, combined with GVC’s precision diagnostic technology.
Collaboration Overview
| Item | Detail |
|---|---|
| Partners | Hua Medicine (HKG: 2552) & GemVCare (GVC) |
| Study Type | Real-world clinical study |
| Therapeutic Focus | Precision diabetes management for type 2 diabetes |
| Drug Candidate | Dorzagliatin (MYHOMSIS) |
| Mechanism | First-in-class glucokinase activator (GKA) |
| Diagnostic Component | GVC’s precision diagnostic technology |
| Geographic Focus | Hong Kong market |
Drug Profile & Mechanism of Action
- Molecule: Dorzagliatin (trade name: MYHOMSIS)
- Target: Glucokinase (glucose sensor)
- Innovation: First-in-class glucokinase activator that improves glucose sensitivity and addresses blood glucose homeostasis regulation failure in type 2 diabetes patients
- Regulatory Status:
- Approved by China NMPA (30 Sep 2022) for monotherapy or combination with metformin
- Approved in Hong Kong (Feb 2026)
- Approved in Macau (Jun 2026)
Regulatory Milestones Timeline
| Date | Milestone | Jurisdiction |
|---|---|---|
| 30 Sep 2022 | Marketing approval for adult type 2 diabetes (mono/combination therapy) | China (NMPA) |
| Feb 2026 | Marketing approval granted | Hong Kong |
| Jun 2026 | Marketing approval granted | Macau |
| Jul 2026 | Real-world clinical study partnership announced | Hong Kong |
Strategic Implications
- Evidence-Based Medicine Enhancement: The collaboration aims to strengthen the clinical evidence base for dorzagliatin specifically in the Hong Kong healthcare context
- Personalized Treatment Approach: Combining GVC’s diagnostic capabilities with Hua Medicine’s therapeutic innovation enables patient stratification and optimized treatment outcomes
- Market Expansion Strategy: Following regulatory approvals across Greater China, this real-world study supports commercial adoption and potential reimbursement negotiations in Hong Kong
- Clinical Data Generation: Expected to produce valuable insights on long-term glycemic control, patient response patterns, and real-world effectiveness compared to standard care
The real-world clinical study represents a significant step toward establishing precision medicine protocols for type 2 diabetes management in Hong Kong, leveraging the unique mechanism of action of dorzagliatin alongside advanced diagnostic tools to potentially improve patient outcomes.-Fineline Info & Tech